Companies › Suzhou HepaThera Biotech
2 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 1; Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HT-101 | – | Phase 2 | Chronic Hepatitis B | Feb 2027 |
| HT-102 | – | Phase 2 | Chronic Hepatitis B | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07245953 | HT-101 | Phase 2 | Chronic Hepatitis B | Infectious disease | Feb 2027 |
| NCT07245953 | HT-102 | Phase 2 | Chronic Hepatitis B | Infectious disease | Feb 2027 |
| NCT07183306 | HT-101 | Phase 1 | Chronic Hepatitis B | Infectious disease | Aug 2027 |
| NCT07183306 | HT-102 | Phase 1 | Chronic Hepatitis B | Infectious disease | Aug 2027 |
No annotated target.
–
TaiMed Biologics Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.